Palatin Technologies, Inc. (PTN) Analysts See $0.02 EPS

September 8, 2018 - By Kristin Houston

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) LogoInvestors sentiment increased to 3.18 in 2018 Q1. Its up 0.97, from 2.21 in 2017Q4. It increased, as 6 investors sold Palatin Technologies, Inc. shares while 5 reduced holdings. 15 funds opened positions while 20 raised stakes. 50.81 million shares or 181.70% more from 18.04 million shares in 2017Q4 were reported.
Moreover, Geode Limited Com has 0% invested in Palatin Technologies, Inc. (NYSEAMERICAN:PTN). 28,000 were accumulated by Lpl Lc. Wealthtrust Axiom Ltd Liability invested in 22,060 shares or 0.01% of the stock. Cubist Systematic Strategies Limited Company holds 55,096 shares or 0% of its portfolio. Blackrock Inc holds 1.22 million shares or 0% of its portfolio. Palisade Capital Mgmt Ltd Llc Nj has 19,010 shares. State Street Corp owns 68,539 shares for 0% of their portfolio. M Secs Incorporated owns 12,289 shares. Cordasco Financial Networks holds 0% or 2,940 shares. Gotham Asset Management Llc holds 45,903 shares or 0% of its portfolio. Manufacturers Life Insur Communication The invested in 0% or 2,361 shares. Bridgeway Cap Inc holds 0.01% or 546,000 shares. Arrowstreet Cap Ltd Partnership has 1.20 million shares. Panagora Asset Mngmt has invested 0% in Palatin Technologies, Inc. (NYSEAMERICAN:PTN). Crestwood Advsr Group Incorporated owns 25,000 shares.

Analysts expect Palatin Technologies, Inc. (NYSEAMERICAN:PTN) to report $0.02 EPS on September, 24.They anticipate $0.05 EPS change or 71.43 % from last quarter’s $0.07 EPS. PTN’s profit would be $4.03M giving it 13.00 P/E if the $0.02 EPS is correct. The stock increased 2.97% or $0.03 during the last trading session, reaching $1.04. About 398,435 shares traded. Palatin Technologies, Inc. (NYSEAMERICAN:PTN) has risen 205.26% since September 8, 2017 and is uptrending. It has outperformed by 192.69% the S&P500.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company has market cap of $209.78 million. The company??s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder . It has a 7.76 P/E ratio. The Company’s drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation.

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.